Drug Trial Radar · NCT05276219
DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,041
Planned (sponsor's estimate)
Start
Sep 14, 2023
Primary completion
May 1, 2027
Study completion May 1, 2027
Sponsor
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Zealand University Hospital; Copenhagen University Hospital, Hvidovre; Herlev Hospital; Bispebjerg Hospital
- First posted
- Mar 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DECONGEST-AHF compares three initial treatments for adults admitted with suspected pulmonary congestion due to acute heart failure: intravenous furosemide, intravenous isosorbide dinitrate, or both medicines together. The aim is to determine which treatment gives patients the most days alive and outside hospital during the first 30 days. The trial is investigator-initiated, multicentre, randomised and blinded, with 1,041 participants allocated equally to three groups. During the first six hours, participants receive repeated boluses of 40 mg furosemide with nitrate placebo, 3 mg isosorbide dinitrate with furosemide placebo, or both active medicines. Doses are repeated at the treating physician's discretion within the protocol limits. Other usual care continues, and treatment may be stopped early if clinically required. An embedded substudy will examine early clinical and haemodynamic responses in 79 participants from the main trial, using repeated bedside measurements during the first 360 minutes. The main trial treatment groups and primary outcome are unchanged.
Conditions
- Pulmonary Edema
- Congestive Heart Failure
- Acute Heart Failure
Interventions
Furosemide InjectionDrug
A diuretic (iv furosemide) strategy for decongestion in acute heart failure
Isosorbide DinitrateDrug
Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure
Furosemide and isosorbide dinitrateDrug
Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Days alive and outside hospitalTime frame: 30 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Herlev University Hospital
Herlev, Denmark · Recruiting
Nordsjællands Hospital
Hillerød, Denmark · Active not recruiting
Hvidovre Hospital
Hvidovre, Denmark · Recruiting
Roskilde Hospital
Roskilde, Denmark · Recruiting
Bispebjerg Hospital
Copenhagen, Copenhagen, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.